Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on EquityReturn on Sales

Summit Therapeutics (SMMT) Net Margin (2016 - 2022)

Historic Net Margin for Summit Therapeutics (SMMT) over the last 6 years, with Q3 2022 value amounting to 7700.0%.

  • Summit Therapeutics' Net Margin changed N/A to 7700.0% in Q3 2022 from the same period last year, while for Sep 2025 it was 3.5231079858176e18%, marking a year-over-year decrease of 3.5231079858176013e22%. This contributed to the annual value of 11174.75% for FY2022, which is 62769100.0% down from last year.
  • Per Summit Therapeutics' latest filing, its Net Margin stood at 7700.0% for Q3 2022.
  • In the past 5 years, Summit Therapeutics' Net Margin ranged from a high of 1423.47% in Q1 2019 and a low of 7700.0% during Q3 2022
  • Its 4-year average for Net Margin is 2504.12%, with a median of 1437.41% in 2018.
  • Per our database at Business Quant, Summit Therapeutics' Net Margin surged by 2185300bps in 2018 and then crashed by -58529500bps in 2019.
  • Quarter analysis of 4 years shows Summit Therapeutics' Net Margin stood at 1581.11% in 2018, then crashed by -333bps to 6841.94% in 2019, then soared by 59bps to 2775.1% in 2020, then crashed by -177bps to 7700.0% in 2022.
  • Its Net Margin stands at 7700.0% for Q3 2022, versus 2775.1% for Q1 2020 and 6841.94% for Q4 2019.